Stegent Equity Advisors Inc. Reduces Stake in AbbVie Inc. $ABBV

Stegent Equity Advisors Inc. trimmed its position in AbbVie Inc. (NYSE:ABBV) by 29.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,750 shares of the company’s stock after selling 3,179 shares during the period. AbbVie comprises 1.4% of Stegent Equity Advisors Inc.’s portfolio, making the stock its 23rd biggest holding. Stegent Equity Advisors Inc.’s holdings in AbbVie were worth $1,686,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Chelsea Counsel Co. bought a new stake in AbbVie during the third quarter valued at about $26,000. Litman Gregory Wealth Management LLC bought a new position in AbbVie in the 4th quarter worth approximately $28,000. Westend Capital Management LLC purchased a new position in AbbVie during the fourth quarter valued at $29,000. Imprint Wealth LLC grew its position in shares of AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares in the last quarter. Finally, Texas Capital Bancshares Inc TX purchased a new position in AbbVie during the 3rd quarter valued at approximately $31,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Down 0.2%

Shares of NYSE ABBV opened at $251.07 on Thursday. AbbVie Inc. has a twelve month low of $184.63 and a twelve month high of $255.99. The firm has a market cap of $443.59 billion, a PE ratio of 123.68, a price-to-earnings-growth ratio of 0.83 and a beta of 0.32. The business has a fifty day simple moving average of $217.86 and a two-hundred day simple moving average of $219.76.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. The firm had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter last year, the firm posted $2.46 earnings per share. On average, research analysts expect that AbbVie Inc. will post 14.28 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. AbbVie’s dividend payout ratio (DPR) is 340.89%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported encouraging Phase 3 data for its venetoclax-based CLL treatment at the EHA 2026 Congress, reinforcing the drug’s safety and efficacy profile and supporting confidence in its hematology franchise.
• Positive Sentiment: AbbVie and Genmab’s lymphoma program met its primary endpoint in a Phase 3 trial, raising the odds of label expansion and a larger commercial opportunity for Epkinly.
• Positive Sentiment: News that AbbVie is acquiring Apogee Therapeutics has been viewed as a growth-supportive move, signaling continued pipeline expansion through M&A.
• Positive Sentiment: AbbVie also highlighted Aquipta’s efficacy for acute migraine following EU approval, adding another potential growth driver in its neuroscience portfolio.
• Neutral Sentiment: Analysts at Erste Group trimmed their FY2026 and FY2027 EPS estimates slightly, but the reductions were small and remained near consensus, so the impact looks limited.
• Negative Sentiment: US lawmakers opened an investigation into AbbVie and other drugmakers over clinical trials conducted in China, which could create headline risk and raise compliance concerns.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ABBV. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Piper Sandler restated an “overweight” rating and issued a $298.00 price target on shares of AbbVie in a research report on Tuesday, June 23rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research note on Monday, June 8th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and an average target price of $253.81.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.